Abstract:Gynecological malignancies are a leading cause of mortality among females worldwide, and difficulties in early diagnosis and acquired drug resistance constitute obstacles to effective therapies. Ovarian cancer causes more deaths than any other cancer of the female reproductive system. Specifically, in females aged 20 to 39 years, cervical cancer is the third leading cause of cancer‑related mortality, and the incidence rates of cervical adenocarcinoma are increasing. Endometrial carcinoma is the most common gynecological cancer in developed countries, such as the United States. Vulvar cancer and uterine sarcomas are considered rare, and therefore require further investigation. Notably, the development of novel treatment options is critical. Previous research has revealed metabolic reprogramming as a distinct feature of tumor cells, which includes aerobic glycolysis. In this instance, cells produce adenosine triphosphate and various precursor molecules through glycolysis, despite oxygen levels being sufficient. This is to meet the energy required for rapid DNA replication. This phenomenon is also known as the Warburg effect. The Warburg effect results in an increased glucose uptake, lactate production and reduced pH values in tumor cells. The results of previous studies have demonstrated that microRNAs (miRNAs/miRs) regulate glycolysis, and participate in tumorigenesis and tumor progression via interactions with glucose transporters, essential enzymes, tumor suppressor genes, transcription factors and multiple cellular signaling pathways that play critical roles in glycolysis. Notably, miRNAs affect the levels of glycolysis in ovarian, cervical and endometrial cancers. The present review article provides a comprehensive overview of the literature surrounding miRNAs in the glycolysis of gynecological malignant cells. The present review also aimed to determine the role of miRNAs as potential therapeutic options rather than diagnostic markers.

Glucose metabolism reprogramming in gynecologic malignant tumors

Mapping the expression and functional landscape of key enzymes in glucose metabolism within human gynecological tumors

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

The Role of Aberrant Metabolism in Cancer: Insights into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer

Role of microRNAs in glycolysis in gynecological tumors (Review)

Breast cancer therapy: from the perspective of glucose metabolism and glycosylation

Advancements in the study of glucose metabolism in relation to tumor progression and treatment

Metabolic Reprogramming and Interventions in Endometrial Carcinoma.

Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments

Glucose Metabolism in Breast Cancer and Its Implication in Cancer Therapy

[Regulation of Tumor Cell Glycometabolism and Tumor Therapy].

Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma

Research progress on the mechanism of glycolysis in ovarian cancer

Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment

Alteration of glucose metabolism and expression of glucose transporters in ovarian cancer

Study on Chemotherapy-induced Disorders of Glucose Metabolism in Patients with Gynecologic Malignant Tumor

Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer

Metabolic reprogramming in epithelial ovarian cancer.

Progress in targeting glycolysis pathway in ovarian cancer

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance